Skip to main content
news

NEWS

CSL Seqirus Canada News Releases

2025

CSL Seqirus Canada News Releases

2025

CSL Seqirus is Fully Prepared to Implement the WHO’s Trivalent Influenza Vaccines Strain Selection for the 2025/26 Canadian Influenza Season

13 Feb 2025

CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2025/26 Canadian influenza season, based on the trivalent strains recommended by the World Health Organization (WHO), which is supported by the National Advisory Committee on Immunization (NACI).1,2

2024

2024

Sixth BARDA Award in Response to Avian Influenza

20 Dec 2024

CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines

20 Dec 2024

CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years.

CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations

20 Dec 2024

CSL Seqirus, a business of CSL (ASX: CSL), announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health.

FLUAD® Adjuvanted Flu Vaccines for Quebec Seniors Aged 65 and Older: CSL Seqirus Welcomes the Comité sur l’Immunisation du Québec (CIQ)’s Recommendation

26 Aug 2024

FLUAD® Influenza vaccine (surface antigen, inactivated, adjuvanted with MF59®) is now preferentially recommended by the Comité sur l’immunisation du Québec (Quebec Immunization Committee, or CIQ) for adults 65 years of age and older.

CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza

30 May 2024

· CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.
· Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and livestock have been reported in the U.S.
· Fourth avian influenza pandemic preparedness award to CSL Seqirus under a multi-year agreement with Biomedical Advanced Research and Development Authority (BARDA).